7 July 2023 in Molecular Psychiatry
GCGiovanna Carello-Collar
JFJoão Pedro Ferrari-Souza
+7
25 December 2023 in Alzheimer's & Dementia
Background: Alzheimer’s disease (AD) is characterized by the extracellular accumulation of amyloid‐β (Aβ) plaques and neuronal deposition of tau tangles, mainly in cortical regions and the hippocampus. Beyond these neuropathological hallmarks, it is suggested that neurotransmission dysfunctions, such as in the γ‐aminobutyric acid (GABA)ergic system, contribute to AD pathophysiology. However, the impact of Aβ and tau in the GABAergic system is still unknown. Thus, we aimed to examine GABA levels in the hippocampus of transgenic mouse models of Aβ and tau.Method: We systematically reviewed the literature following the PRISMA 2020 guidelines. We searched PubMed and Web of Science databases for studies reporting GABA levels in the 3xTg‐AD and 5xFAD mouse models. These models present APP and PSEN1 mutations, but the 3xTg‐AD also harbors the MAPT P310L tau mutation, which is found in frontotemporal dementia.Result: The search identified 3,576 articles. Six met the inclusion criteria (n = 26 3xTg‐AD and 26 wild‐type (WT); n = 16 5xFAD and 17 WT). The studies reported no significant differences in the levels of GABA in the hippocampus of 3xTg‐AD mice compared to their WT, but GABA levels decreased as a function of age. By contrast, the 5xFAD mouse model presented higher levels of GABA than their WT littermates.Conclusion: Here, we show no significant changes in GABA levels in the hippocampus of 3xTg‐AD mice, whereas the levels of GABA were increased in the 5xFAD. Interestingly, the model harboring APP, PSEN1, and MAPT P310L mutations does not present changes in hippocampal levels of GABA. Our results suggest that Aβ alters GABA levels in the hippocampus, which may be an early change in AD. In addition, hippocampal GABAergic changes seem sensitive to different pathological features of AD.
25 December 2023 in Alzheimer's & Dementia
Background: Rodent models that overexpress mutations in the amyloid precursor protein (APP) and presenilin 1 (PSEN1) genes have been widely applied in Alzheimer’s disease (AD) research. These models classically present amyloid plaque deposition in cortical and hippocampal areas and neurotransmission changes. Although amyloid‐related glutamatergic abnormalities have been extensively described, little is known about its effects on the GABAergic system. Thus, we aimed to examine GABA levels in the cortex of two transgenic amyloid mouse models.Method: We systematically reviewed the literature following the PRISMA 2020 guidelines. PubMed and Web of Science databases were searched for studies reporting GABA levels in the cortex of APPswe/PSEN1dE9 and Tg2576 mice. We opted to evaluate only animals with mature amyloid plaques in their cortices, according to each mouse model previous characterization.Result: The search identified 3576 papers. Seven records met the inclusion criteria (Tg2576: n = 21, mean age ± standard deviation (SD) = 14.7 ± 3.7 months; controls: n = 21; APPswe/PSEN1dE9: n = 25, mean age ± SD = 8.5 ± 4.1 months; controls: n = 25). Five out of seven results reported non‐significant differences in the GABA levels in multiple cortical regions, such as the frontal, pre‐frontal, and rhinal cortices of the Tg2576 mouse model, but two studies described that GABA is significantly decreased. Furthermore, all studies with the APP/PSEN1 model consistently reported decreased cortical GABA levels. Figure 1 provides a summary of our findings.Conclusion: Our results suggest that APP and PSEN1 mutations may contribute to the decrease in the levels of GABA in cortical regions of amyloid models. Future meta‐analyses and clinical studies are needed to ascertain the consistency of the reported results.